AN2 TherapeuticsANTX
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 37 institutions reported holding AN2 Therapeutics Inc. (ANTX) in their 13F filings, down 1 from Q1 2025. 8 opened new positions and 9 sold out. The largest holders were Almitas Capital LLC ($1.5M), Vanguard Group Inc. ($1.1M) and Pfizer Inc ($758K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- AN2 Therapeutics Inc.
- CUSIP
- 037326105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $1.2M |
| Exits | 9 | $9.9M |
All 13F filers, Q1 2025 → Q2 2025: 1,543,577 shares bought and 7,599,850 shares sold, net −6,056,273 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 37 holders
| Almitas Capital LLC | 0.38% | Add +8.8% | 1,428,323 | $1.5M |
| Vanguard Group Inc. | 0.00% | No change | 1,035,947 | $1.1M |
| Pfizer Inc | 0.13% | No change | 715,295 | $758K |
| Peapod Lane Capital LLC | 0.62% | Add +0.3% | 582,770 | $618K |
| Stonepine Capital Management, LLC | 0.57% | New | 544,494 | $577K |
| Landscape Capital Management, L.L.C. | 0.04% | New | 495,396 | $525K |
| Bank of Nova Scotia | 0.00% | No change | 459,194 | $487K |
| Bank of Montreal | 0.00% | No change | 422,077 | $447K |
| Renaissance Technologies | 0.00% | Add +8.2% | 398,854 | $423K |
| Bank of America Corp. | 0.00% | Add +0.0% | 385,511 | $409K |
| BlackRock, Inc. | 0.00% | Add +6.2% | 319,295 | $338K |
| Two Sigma Advisers, LP | 0.00% | Reduce -39.4% | 269,600 | $286K |
| Geode Capital Management, LLC | 0.00% | Reduce -1.8% | 249,351 | $264K |
| Two Sigma Investments, LP | 0.00% | Reduce -30.7% | 238,347 | $253K |
| Morgan Stanley | 0.00% | Add +59314.3% | 178,243 | $189K |
| State Street Corp. | 0.00% | No change | 87,002 | $92K |
| Rangeley Capital, LLC | 0.09% | Add +30.0% | 65,000 | $69K |
| UBS Group AG | 0.00% | Reduce -41.5% | 62,000 | $66K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 59,900 | $63K |
| Susquehanna International Group, LLP | 0.00% | New | 45,320 | $48K |
| Northern Trust Corp. | 0.00% | No change | 43,196 | $46K |
| Captrust Financial Advisors | 0.00% | Add +300.0% | 40,000 | $42K |
| XTX Topco Ltd | 0.00% | New | 26,044 | $28K |
| Integrated Wealth Concepts LLC | 0.00% | No change | 25,000 | $27K |
| Private Advisor Group, LLC | 0.00% | No change | 22,500 | $24K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -14.9% | 17,115 | $18K |
| Citadel Advisors | 0.00% | New | 12,497 | $13K |
| HRT Financial LP | 0.00% | New | 12,678 | $13K |
| Federated Hermes, Inc. | 0.00% | No change | 12,237 | $13K |
| Qube Research & Technologies Ltd | 0.00% | No change | 10,184 | $11K |
| Squarepoint Ops LLC | 0.00% | New | 10,062 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +155.2% | 5,313 | $6K |
| Highline Wealth Partners LLC | 0.00% | New | 5,000 | $5K |
| Innovative Advisory Group, LLC | 0.00% | No change | 1,170 | $1K |
| BNP Paribas Financial Markets | 0.00% | No change | 312 | $331 |
| Osaic Holdings, Inc. | 0.00% | No change | 300 | $318 |
| SBI Securities Co., Ltd. | 0.00% | No change | 200 | $212 |
"% of holder's portfolio" is ANTX's weight in each manager's 13F, not the share of AN2 Therapeutics Inc. the manager owns.